This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Preventing Pain After Heart Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Barts & The London NHS Trust.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Barts & The London NHS Trust
ClinicalTrials.gov Identifier:
NCT01480765
First received: November 24, 2011
Last updated: November 11, 2012
Last verified: May 2012
  Purpose
The use of pre-emptive analgesia to prevent pain following sternotomy for cardiac surgery

Condition Intervention Phase
Pain Hyperalgesia Chronic Illness Neuropathic Pain Drug: Pregabalin Drug: Ketamine infusion Drug: Placebo capsules Drug: Placebo infusion Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery.

Resource links provided by NLM:


Further study details as provided by Barts & The London NHS Trust:

Primary Outcome Measures:
  • Numerical Rating Scale (NRS) pain score (around sternotomy incision site) post surgery, at rest and following 3 maximal coughs. [ Time Frame: 3 and 6 months post sternotomy ]

Secondary Outcome Measures:
  • Total morphine consumption at 24 hours post surgery [ Time Frame: 24 hours post surgery ]
  • Visual Analogue Scale (VAS) scores at 24 hrs post surgery, at rest and following 3 maximal coughs [ Time Frame: 24 hours post surgery ]
  • Sedation (including pCO2) and nausea scores at 24 hours post surgery [ Time Frame: 24 hours post surgery ]
  • Side effect episodes (dizziness, confusion, blurred vision) [ Time Frame: First 48 hours ]
  • Time to extubation [ Time Frame: Post op recovery period ]
  • Length of stay in intensive care and hospital [ Time Frame: Post operative - acute ]
  • 28 day mortality [ Time Frame: 28 days post surgery ]
  • Neuropathic pain score [ Time Frame: 3 and 6 months post surgery ]
    S-LANSS (Short form Leeds Assessment of Neuropathic Symptoms and Signs)

  • Quality of Life [ Time Frame: 3 and 6 months ]
    EQ-5D validated scoring scale

  • Survival [ Time Frame: 3 and 6 months ]
  • QST measurements [ Time Frame: Pre op and post op at 72hrs and 3 months ]
    Pain Pressure Thresholds (PPT) using algometry, both pre and post Diffuse Noxious Inhibitory Control (DNIC) Tactile and Pain Detection Thresholds with mechanical static stimulus using Von Frey hairs (VFH) Dynamic assessment of temporal summation and secondary hyeralgesia with VFH


Estimated Enrollment: 150
Study Start Date: November 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Control: Placebo + Placebo
Placebo capsules and Placebo infusion
Drug: Placebo capsules
Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
Drug: Placebo infusion
Normal saline placebo intravenous infusion for 48 hours
Active Comparator: Pregabalin and Placebo infusion
Pregabalin capsules and Placebo infusion
Drug: Pregabalin
150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
Drug: Placebo infusion
Normal saline placebo intravenous infusion for 48 hours
Active Comparator: Pregabalin + Ketamine infusion
Pregabalin capsules + Ketamine infusion
Drug: Pregabalin
150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
Drug: Ketamine infusion
0.1mg/kg/hr for 48 hours post operatively

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed Consent
  • First time sternotomy for all cardiac surgery
  • Patient aged 18 - 80 years

Exclusion Criteria:

  • Emergency surgery (decision to operate taken on the day of surgery)
  • Previous sternotomy
  • Preoperative renal failure (eGFR <60 ml/min)
  • History of chronic non-anginal pain
  • Chronic pain medication other than paracetamol and non-steroidal anti-inflammatory drugs
  • Concurrent use of oxycodone, lorazepam, or ethanol.
  • Concurrent use of any drugs for neuropathic pain e.g. antiepileptics, antidepressants
  • Allergy to pregabalin, gabapentin or ketamine
  • Pregnancy
  • Limited understanding of numerical scoring scales
  • Previous participation in other trials investigating analgesic agents or any IMP in previous three months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01480765

Contacts
Contact: Sibtain Anwar, MA MB FRCA +44 2034655361 sibtainanwar@bartshealth.nhs.uk
Contact: Chhaya Sharma, MB BS FRCA +44 2034655361 chhaya.sharma@bartshealth.nhs.uk

Locations
United Kingdom
Pain and Ananesthesia Research Centre, Barts and The London NHS Trust Recruiting
London, United Kingdom, EC1A 7BE
Contact: Sibtain Anwar, MA MB FRCA    +442034655361    sibtain.anwar@bartshealth.nhs.uk   
Sub-Investigator: Sibtain Anwar, MA MB FRCA         
Principal Investigator: Richard Langford, FRCA         
Sub-Investigator: Chhaya Sharma, MB BS FRCA         
Sub-Investigator: Junia Rahman, MB BS FRCA         
Sponsors and Collaborators
Barts & The London NHS Trust
Investigators
Study Director: Sibtain Anwar, MA MB FRCA Barts and The London NHS Trust
  More Information

Responsible Party: Barts & The London NHS Trust
ClinicalTrials.gov Identifier: NCT01480765     History of Changes
Other Study ID Numbers: Reda 007583
2010-024462-21 ( Registry Identifier: EudraCT )
11/H0703/7 ( Registry Identifier: UK REC Ref )
Study First Received: November 24, 2011
Last Updated: November 11, 2012

Additional relevant MeSH terms:
Neuralgia
Hyperalgesia
Chronic Disease
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Somatosensory Disorders
Sensation Disorders
Disease Attributes
Pathologic Processes
Ketamine
Pregabalin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anticonvulsants
Calcium Channel Blockers

ClinicalTrials.gov processed this record on June 22, 2017